{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:24:38Z","timestamp":1793841878965,"version":"4.6.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.annonc.2026.10.096","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:55:23Z","timestamp":1792756523000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant nivolumab plus gemcitabine\u2013cisplatin followed by postsurgical adjuvant nivolumab versus neoadjuvant gemcitabine\u2013cisplatin in patients with muscle-invasive bladder cancer: final results from the phase III CA017-078 trial"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1010-9611","authenticated-orcid":false,"given":"G.","family":"Sonpavde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4407-7881","authenticated-orcid":false,"given":"M.S.","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.D.","family":"Galsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.E.","family":"Gschwend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Sade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bimbatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9973-4869","authenticated-orcid":false,"given":"G.","family":"Schepisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"V\u00e1zquez Est\u00e9vez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Panay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Schinzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kotsakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Jeyamohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7137-3953","authenticated-orcid":false,"given":"J.","family":"Neely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Jacques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8511-3914","authenticated-orcid":false,"given":"S.","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3007-2756","authenticated-orcid":false,"given":"A.","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.annonc.2026.10.096_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.annonc.2025.09.139","article-title":"Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274","volume":"37","author":"Galsky","year":"2026","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.10.096_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/JU.0000000000003981","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/SUO guideline (2017; amended 2020, 2024)","volume":"212","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.annonc.2026.10.096_bib3","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines","volume":"87","author":"van der Heijden","year":"2025","journal-title":"Eur Urol"},{"issue":"27","key":"10.1016\/j.annonc.2026.10.096_bib4","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1200\/JCO-25-00718","article-title":"Muscle-invasive bladder cancer: a watershed moment","volume":"43","author":"Galsky","year":"2025","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2026.10.096_bib5","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.annonc.2026.10.096_bib6","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration","volume":"48","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.annonc.2026.10.096_bib7","year":"2026"},{"issue":"22","key":"10.1016\/j.annonc.2026.10.096_bib8","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.annonc.2026.10.096_bib9","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.21.02051","article-title":"Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial","volume":"40","author":"Pfister","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.10.096_bib10","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1470-2045(23)00587-9","article-title":"Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study","volume":"25","author":"Pfister","year":"2024","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2026.10.096_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.108329","article-title":"Comparative efficacy of perioperative systemic therapies for muscle-invasive bladder cancer: a network meta-analysis of randomized trials","volume":"11","author":"Maiorano","year":"2026","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.annonc.2026.10.096_bib12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.24.00340","article-title":"Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from CheckMate 274","volume":"43","author":"Galsky","year":"2025","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.annonc.2026.10.096_bib13","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.10.096_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.eururo.2026.01.015","article-title":"Updated 5-year survival results from PURE-01, a phase 2 study of neoadjuvant pembrolizumab followed by radical cystectomy in patients with muscle-invasive bladder cancer","volume":"90","author":"Tateo","year":"2026","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.annonc.2026.10.096_bib15","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","article-title":"Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder","volume":"82","author":"Szabados","year":"2022","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.annonc.2026.10.096_bib16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa2401726","article-title":"Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"392","author":"Apolo","year":"2025","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.annonc.2026.10.096_bib17","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"suppl 6","key":"10.1016\/j.annonc.2026.10.096_bib18","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1200\/JCO.2020.38.6_suppl.439","article-title":"Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy","volume":"38","author":"Gupta","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2026.10.096_bib19","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa2601486","article-title":"Enfortumab vedotin and pembrolizumab in cisplatin-eligible bladder cancer","volume":"395","author":"Galsky","year":"2026","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.annonc.2026.10.096_bib20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.euo.2023.05.012","article-title":"Circulating tumor DNA as a predictive and prognostic biomarker in the perioperative treatment of muscle-invasive bladder cancer: a systematic review","volume":"7","author":"Crupi","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"7867","key":"10.1016\/j.annonc.2026.10.096_bib21","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.annonc.2026.10.096_bib22","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.euo.2025.11.001","article-title":"Circulating tumor DNA in muscle-invasive bladder cancer: promise, pitfalls, and path forward","volume":"9","author":"Cerrato","year":"2026","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.annonc.2026.10.096_bib31","series-title":"AJCC Cancer Staging Manual","year":"2017"},{"issue":"18","key":"10.1016\/j.annonc.2026.10.096_bib24","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.096_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2026.06.006","article-title":"Evaluating the surrogacy of pathological complete response at radical cystectomy in neoadjuvant-based muscle-invasive bladder cancer trials","author":"Scilipoti","year":"2026","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.10.096_bib26","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.euo.2024.07.001","article-title":"Association of tumor-informed circulating tumor DNA detectability before and after radical cystectomy with disease-free survival in patients with bladder cancer","volume":"8","author":"Sfakianos","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"23","key":"10.1016\/j.annonc.2026.10.096_bib27","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1158\/1078-0432.CCR-23-1860","article-title":"Circulating tumor DNA analysis in advanced urothelial carcinoma: insights from biological analysis and extended clinical follow-up","volume":"29","author":"Lindskrog","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.annonc.2026.10.096_bib28","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO-25-02382","article-title":"Gemcitabine intravesical system plus cetrelimab or cetrelimab alone as neoadjuvant therapy in muscle-invasive bladder cancer: SunRISe-4 primary analysis and biomarker results","volume":"44","author":"Necchi","year":"2026","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.annonc.2026.10.096_bib29","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426068778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426068778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:25:08Z","timestamp":1793838308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426068778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":29,"alternative-id":["S0923753426068778"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.10.096","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant nivolumab plus gemcitabine\u2013cisplatin followed by postsurgical adjuvant nivolumab versus neoadjuvant gemcitabine\u2013cisplatin in patients with muscle-invasive bladder cancer: final results from the phase III CA017-078 trial","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.10.096","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}